| Literature DB >> 36018539 |
Luca Urso1,2, Alberto Nieri1, Ilaria Rambaldi1, Angelo Castello3, Licia Uccelli1,2, Corrado Cittanti1,2, Stefano Panareo4, Irene Gagliardi5, Maria Rosaria Ambrosio5, Maria Chiara Zatelli6, Mirco Bartolomei1.
Abstract
In the last 10 years, several literature reports supported radioligand therapy (RLT) in neoadjuvant settings for pancreatic neuroendocrine tumors (PanNETs). Indeed, primary tumor shrinkage has been frequently reported following RLT in unresectable or borderline resectable PanNETs. Moreover, RLT-induced intratumoral modifications facilitate surgery, both on primary tumor and metastasis, having a great impact on progression free survival (PFS), overall survival (OS) and quality of life (QoL). However, prospective controlled investigations are necessary to confirm preliminary data and to define the best RLT scheme and the ideal patient that, in a multidisciplinary approach, should be referred to neoadjuvant RLT.Entities:
Keywords: 177Lu; 90Y; Neoadjuvant Therapy; Neuroendocrine Tumors; Pancreatic Surgery; Peptide Receptor Radionuclide Therapy; Radioligand Therapy
Mesh：
Year: 2022 PMID： 36018539 PMCID： PMC9585010 DOI： 10.1007/s12020-022-03170-0
Source DB: PubMed Journal: Endocrine ISSN： 1355-008X Impact factor: 3.925